Meeting
2023 ASCO Annual Meeting
A prospective, open-label, randomized, controlled trial of radiofrequency ablation versus stereotactic body radiation therapy for recurrent small hepatocellular carcinoma.
Authors
Yaojun Zhang
Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
Yaojun Zhang , Mian Xi , Minshan Chen , Li Xu , Shi-Liang Liu , Mengzhong Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04047173
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4096)
DOI
10.1200/JCO.2023.41.16_suppl.4096
Abstract #
4096
Poster Bd #
417
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A multicenter nonrandomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF cohort trial).
First Author: Ryosuke Tateishi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Protocol for open-label, randomised, controlled trial of intensive surveillance vs. standard postoperative follow-up in patients undergoing surgical resection for oesophageal and gastric cancer (SARONG trial).
First Author: Sheraz Markar
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of atezolizumab/bevacizumab combination therapy in BCLC-C cirrhotic patients with hepatocellular carcinoma (HCC) according to the type of disease progression.
First Author: Spyridon Pantzios
Poster
2023 ASCO Gastrointestinal Cancers Symposium
IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early-stage hepatocellular carcinoma (HCC).
First Author: Arndt Vogel